Company news

Harmony Biosciences Holdings, Inc. news in 2026

Harmony Biosciences Holdings, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile

November 4, 2026

Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026

October 20, 2026

Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth

October 12, 2026

Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

October 1, 2026

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

September 3, 2026

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

August 27, 2026

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

August 4, 2026

Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

July 21, 2026

Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

July 16, 2026

Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

June 11, 2026

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

May 7, 2026

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

April 23, 2026

Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting

April 16, 2026

Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer

April 13, 2026

Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

April 1, 2026

Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference

March 30, 2026

Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

February 24, 2026

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

February 17, 2026

Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

February 10, 2026

Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation

January 12, 2026

Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 7, 2026

Calls in 2026

Decks in 2026